As a phosphorus supplement, each tablet supplies 20% of the U.S. Recommended Daily Allowance (U.S. RDA) of phosphorus for adults and children over 4 years of age. Phosphorous Tablets increases urinary phosphate and pyrophosphate. Contraindications This product is contradicted in patients with infected phosphate stones in the urinary tract, in patients with severely impaired renal function (less than 30% of normal)...
Phosphorous Supplement Tablets should be taken with a full glass of water, with food, and at bedtime. Adults: One tablet four times to eight times daily. Pediatric patients over 4 years of age: One tablet four times daily. Pediatric Patients under 4 years of age: Use only as directed by a licensed physician.
Phosphorus Dietary Supplement -supplying 250 mg per tablet
71351-011-01
DESCRIPTION
Phosphorous Tablets is a prescription phosphorus dietary supplement - supplying 250 mg phosphorus per tablet for use in the dietary management of hypophosphatemia and should be administered under the supervision of a licensed medical practitioner.
| Serving Size: 1 tablet | ||
| Servings per Container: 100 | ||
| Amount per Serving | %Daily Value | |
| Sodium | 298 mg | 13% |
| Potassium | 45 mg | 1% |
| Phosphorus | 250 mg | 20% |
| (from a minimum of: 852 mg of Dibasic Sodium Phosphate, 155 mg of Monobasic Potassium Phosphate, 130 mg of Monobasic Sodium Phosphate) | ||
Other Ingredients
Microcrystalline Cellulose, Povidone, Coating (Hypromellose, Titanium Dioxide and Polyethylene Glycol), Croscarmellose Sodium, Stearic Acid, Magnesium Stearate, Silicon Dioxide.
As a phosphorus supplement, each tablet supplies 20% of the U.S. Recommended Daily Allowance (U.S. RDA) of phosphorus for adults and
children over 4 years of age. Phosphorous Tablets increases urinary phosphate and pyrophosphate.
Contraindications
This product is contradicted in patients with infected phosphate stones in the urinary tract, in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia.
General
This product contains potassium and sodium and should be used with caution if clinical management of these elements is desired. Some individuals may experience a mild laxative effect during the first few days of phosphate supplementation; lower the daily dose until this effect subsides or, if necessary, discontinue the use of the product. Caution should be exercised when prescribing this product in the following conditions: Cardiac disease (particularly in patients receiving digitalis); severe adrenal insufficiency (Addison's disease); acute dehydration; severe renal insufficiency; renal function impairment or chronic renal disease; extensive tissue breakdown (such as with severe burns); myotonia congenita; cardiac failure; cirrhosis of the liver or severe hepatic disease; peripheral or pulmonary edema; hypernatremia; hypertension; toxemia of pregnancy, hypoparathyroidism; and acute pancreatitis. High serum phosphate levels may increase the incidence of extraskeletal calcification.
Information for Patients
Patients with kidney stones may pass old stones when phosphate supplementation is started and should be warned of this possibility. Patients should be advised to avoid the use of antacids containing aluminum, magnesium, or calcium because they may prevent the absorption of phosphate.
Laboratory Tests
Careful monitoring of renal function and serum calcium, phosphorus, potassium, and sodium may be required at periodic intervals during phosphate supplementation. Other tests may be warranted in some patients, depending on conditions.
Drug Interactions The use of antacids containing magnesium, aluminum, or calcium in conjunction with phosphate preparations may bind the phosphate and prevent its absorption. Concurrent use of antihypertensive drugs or corticosteroids with sodium phosphate may result in hypernatremia. Calcium-containing preparations and/or Vitamin D may antagonize the effects of phosphates in the treatment of hypercalcemia. Potassium-containing medication or potassium-sparing diuretics may cause hyperkalemia. Patients should have serum potassium level determinations at periodic intervals.
Carcinogenesis, Mutagenesis, Impairment of Fertility
No long term or reproduction studies in animals or humans have been performed with Phosphorous Tablets to evaluate its carcinogenic, mutagenic, or impairment of fertility potential.
Pregnancy and Lactation
Animal reproduction studies have not been conducted with Phosphorous Tablets. It is also not known whether this product can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. This product should be given to a pregnant woman only if clearly needed.
It is not known whether this product is excreted in human milk. Because many substances are excreted in human milk, caution should be exercised when this product is administered to a nursing woman.
Pediatric Use: See DIRECTIONS FOR USE.
Gastrointestinal upset (diarrhea, nausea, stomach pain, or vomiting) may occur with phosphate supplementation. Bone and joint pain and possibly osteomalacia could occur.
Adverse effects due to sodium or potassium may be observed: headache; dizziness; mental confusion; seizures; weakness or heaviness of legs; unusual tiredness or weakness; numbness, tingling, pain or weakness of hands or feet; numbness or tingling around lips; fast or irregular heartbeat; shortness of breath or troubled breathing; swelling of feet or lower legs; unusual weight gain; low urine output; unusual thirst.
Phosphorous Supplement Tablets should be taken with a full glass of water, with food, and at bedtime.
Adults: One tablet four times to eight times daily.
Pediatric patients over 4 years of age: One tablet four times daily.
Pediatric Patients under 4 years of age: Use only as directed by a licensed physician.
Store at 20° to 25°C (68° to 77°F). Excursions permitted to 15° to 30°C (59° to 86°F). Protect from light and moisture. Dispense in a tight, light-resistant container.
HOW SUPPLIED
Phosphorous Tablets is supplied as white tablet dispensed in bottles of 100 tablets.
71351-011-01
KEEP THIS OUT OF REACH OF CHILDREN
Call your licensed medical practitioner about side effects. You may report side effects by calling Brookfield Pharmaceuticals at
1-888-997-1351 or FDA at 1-800-FDA-1088.
Manufactured for:
Brookfield Pharmaceuticals, LLC
Brookfield, Wl 53005
MADE IN USA
Rev. 10/21
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 200251 | sodium phosphate, dibasic 852 MG / potassium phosphate, monobasic 155 MG / sodium phosphate, monobasic 130 MG Oral Tablet | PSN | 1 |
| 200251 | potassium phosphate 155 MG / sodium phosphate, dibasic 852 MG / sodium phosphate, monobasic 130 MG Oral Tablet | SCD | 1 |
| 200251 | K+ phosphate 155 MG / Sodium Phosphate, Dibasic 852 MG / Sodium Phosphate, Monobasic 130 MG Oral Tablet | SY | 1 |
| 200251 | Pot phosphate 155 MG / Sodium Phosphate, Dibasic 852 MG / Sodium Phosphate, Monobasic 130 MG Oral Tablet | SY | 1 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| efd58dcf-540a-4531-8766-e713129ca6f2 | Product name | 1 | 20250307 |
| 4b7700e3-6e0e-45e5-9d22-6f754d61386e | Product name | 2 | 20250304 |
| 726062af-1135-4707-a1d7-57256991bbf9 | Product name | 2 | 20250226 |
| 7cda52fc-125f-421c-8fea-bc1974370c49 | Product name | 2 | 20180703 |
| 0ca1d589-929b-4b33-bc5b-1d84abdafa6a | Product name | 1 | 20150324 |
| fc363c46-397b-4476-ac0f-70e43e8e4592 | Product name | 1 | 20150324 |
| 19c71a3d-ed9c-166b-a7e5-38c250c35631 | Product name | 1 | 20140508 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 71351-011-01 | Phosphorous Dietary Supplement | 100 in 1 BOTTLE, PLASTIC | TABLET | 100 | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 71351-011 | 71351-011-01 |
Every source-derived ingredient row is available through these pages.
Adverse event summaries are temporarily unavailable. Other product information remains available.